Chlorin e6 and BLZ945 Based Self‐Assembly for Photodynamic Immunotherapy Through Immunogenic Tumor Induction and Tumor‐Associated Macrophage Depletion

Author:

Huang Chu‐Yu1,Zhao Lin‐Ping1,Rao Xiao‐Na1,Zheng Rong‐Rong1,Liu Zhi‐Shan1,Cai Hua2,Zhang Wei3,Chen A‐Li3,Xu Lin2,Li Shiying1ORCID

Affiliation:

1. The Fifth Affiliated Hospital Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology the NMPA and State Key Laboratory of Respiratory Disease the School of Pharmaceutical Sciences Guangzhou Medical University Guangzhou 511436 P. R. China

2. Department of Geriatric Cardiology General Hospital of the Southern Theatre Command People's Liberation Army (PLA) and Guangdong Pharmaceutical University Guangzhou 510016 P. R. China

3. Center for Drug Research and Development Guangdong Provincial Key Laboratory of Advanced Drug Delivery System Guangdong Pharmaceutical University Guangzhou 510006 P. R. China

Abstract

AbstractImmunotherapeutic effect is restricted by the nonimmunogenic tumor phenotype and immunosuppression behaviors of tumor‐associated macrophages (TAMs). In this work, a drug self‐assembly (designated as CeBLZ) is fabricated based on chlorin e6 (Ce6) and BLZ945 to activate photodynamic immunotherapy through tumor immunogenic induction and tumor‐associated macrophage depletion. It is found that Ce6 tends to assemble with BLZ945 without any drug excipients, which can enhance the cellular uptake, tumor penetration, and blood circulation behaviors. The robust photodynamic therapy effect of CeBLZ efficiently suppresses the primary tumor growth and also triggers immunogenic cell death to reverse the nonimmunogenic tumor phenotype. Moreover, CeBLZ can deplete TAMs in tumor tissues to reverse the immunosuppression microenvironment, activating abscopal effect for distant tumor inhibition. In vitro and in vivo results confirm the superior antitumor effect of CeBLZ with negligible side effect, which might promote the development of sophisticated drug combinations for systematic tumor management.

Funder

National Key Research and Development Program of China

National Natural Science Foundation of China

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3